Pulmongene Announces First Patient Dosed in Phase 1b Clinical Trial Evaluating PMG1015 in Idiopathic Pulmonary Fibrosis Patients 2023-07-05 On July 5, 2023, Pulmongene Ltd. announced that its inv […] Pulmongene Announces First Patient Dosed in Phase 1b Clinical Trial Evaluating PMG1015 in Idiopathic Pulmonary Fibrosis Patients Read More »
FDA Grants Orphan Drug Designation to Pulmongene’s PMG1015 for treatment of Idiopathic Pulmonary Fibrosis (IPF) 2023-02-17 On February 17th, 2023 , Pulmongene Ltd. announced that FDA Grants Orphan Drug Designation to Pulmongene’s PMG1015 for treatment of Idiopathic Pulmonary Fibrosis (IPF) Read More »
